Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Post-transplant Cyclophosphamide for GVHD Prophylaxis
NCT02294552Phase 2Completed
- Start
- Oct 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) (3 arms). Primary endpoint: Incidence of acute and chronic GVHD, requiring treatment at 365 days. Started Oct 2014; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02294552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294552.